Moreover, blockade of the proinflammatory cytokine IL-17a with secukinumab, a fully human selective anti-IL-17a monoclonal antibody, is a valid therapeutic approach and may be useful in the treatment of psoriasis, Rheumatoid Arthritis (RA), and noninfectious uveitis (92). Here, IL17A is linked to rheumatoid arthritis.